Company intelligence / Profile preview
OriCell Therapeutics
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
OriCell Therapeutics has demonstrated promising early clinical results with its autologous CAR-T therapies targeting GPRC5D in relapsed/refractory multiple myeloma. The company received FDA IND approval in December 2023, NMPA IND approval in August 2023, and FDA Orphan Drug Designation in October 2022. Clinical data have been presented at major conferences such as ASCO and EHA, with follow-up results published in The Lancet Haematology.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
Strategic cooperation agreement with Cytiva signed November 2022.
Beyond the preview
Go deeper on OriCell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OriCell Therapeutics.